Table 1.

Baseline characteristics by treatment group (pooled mITT populations)

Variable	Gocovri (n = 100)	Placebo (n = 96)
Age, years	64.2 (9.5)	65.3 (8.8)
Male sex, %	54.0	57.3
White race, %	96.0	92.7
Duration of Parkinson’s disease, years	9.8 (4.7)	9.7 (4.1)
Duration of levodopa treatment, years	7.8 (3.9)	7.6 (4.1)
Duration of dyskinesia, years	4.0 (3.1)	3.6 (2.5)
OFF time, h/day	3.0 (2.3)	2.6 (2.0)
MDS-UPDRS Part II score
Total score	15.1 (6.6)	15.3 (5.9)
M-EDL item
2.1. Speech	1.3 (1.0)	1.3 (1.0)
2.2. Saliva and drooling	1.3 (1.2)	1.2 (1.1)
2.3. Chewing and swallowing	0.4 (0.7)	0.5 (0.7)
2.4. Eating tasks	0.9 (0.8)	1.0 (0.7)
2.5. Dressing	1.2 (0.7)	1.2 (0.7)
2.6. Hygiene	0.9 (0.6)	0.8 (0.6)
2.7. Handwriting	1.5 (1.1)	1.6 (1.2)
2.8. Doing hobbies and other activities	1.5 (0.9)	1.4 (0.8)
2.9. Turning in bed	1.1 (0.7)	1.1 (0.8)
2.10. Tremor	1.3 (1.0)	1.2 (0.9)
2.11. Getting out of a bed, a car, or a deep chair	1.5 (1.0)	1.4 (1.0)
2.12. Walking and balance	1.4 (1.0)	1.4 (1.0)
2.13. Freezing	1.0 (1.1)	1.2 (1.1)

Data are presented as mean (SD) unless otherwise noted

MDS-UPDRS Movement Disorder Society Unified Parkinson’s Disease Rating Scale, M-EDL motor aspects of experiences of daily living, mITT modified intent to treat